Moritz Schmelzle1, Jan Schulte Esch, Simon C Robson. 1. Liver Center and Transplantation Institute, Department of Medicine and Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Xenotransplantation may become clinically feasible once the mechanisms of graft loss and rejection are better understood. Inflammatory reactions to vasculature of grafted pig organs and pancreatic islets have been linked to procoagulant activation and consumption with resulting thrombosis that precludes long-term function. Although development of alpha-1,3-galactosyltransferase gene-knockout swine with removal of a dominant xenoantigen has been an important advance, major problems still persist. RECENT FINDINGS: Consumptive coagulopathy and platelet sequestration are initiated by immune responses associated with xenograft rejection and are exacerbated by putative intrinsic functional incompatibilities. Thrombotic processes together with progressive xenograft microangiopathy and infarction are intertwined with humoral immune reactions that may be secondary, at least in part, to 'natural' or elicited nongalactosyl antibodies. These immune responses are further exacerbated by the documented intrinsic molecular incompatibilities in the vascular regulation of blood clotting and extracellular nucleotide homeostasis between discordant species. Hence, limited benefits have been achieved with currently available pharmacological antithrombotics and anticoagulants. SUMMARY: Proposed strategies to tackle this problem will include optimal immunosuppressive interventions, attempts to induce tolerance, judicious and more effective use of anti-thrombotics with development of mutant swine either transgenic for human anticoagulants and thromboregulatory factors or null for defined porcine procoagulants.
PURPOSE OF REVIEW: Xenotransplantation may become clinically feasible once the mechanisms of graft loss and rejection are better understood. Inflammatory reactions to vasculature of grafted pig organs and pancreatic islets have been linked to procoagulant activation and consumption with resulting thrombosis that precludes long-term function. Although development of alpha-1,3-galactosyltransferase gene-knockout swine with removal of a dominant xenoantigen has been an important advance, major problems still persist. RECENT FINDINGS:Consumptive coagulopathy and platelet sequestration are initiated by immune responses associated with xenograft rejection and are exacerbated by putative intrinsic functional incompatibilities. Thrombotic processes together with progressive xenograft microangiopathy and infarction are intertwined with humoral immune reactions that may be secondary, at least in part, to 'natural' or elicited nongalactosyl antibodies. These immune responses are further exacerbated by the documented intrinsic molecular incompatibilities in the vascular regulation of blood clotting and extracellular nucleotide homeostasis between discordant species. Hence, limited benefits have been achieved with currently available pharmacological antithrombotics and anticoagulants. SUMMARY: Proposed strategies to tackle this problem will include optimal immunosuppressive interventions, attempts to induce tolerance, judicious and more effective use of anti-thrombotics with development of mutant swine either transgenic for human anticoagulants and thromboregulatory factors or null for defined porcine procoagulants.
Authors: Geon A Kim; Eun Mi Lee; Bumrae Cho; Zahid Alam; Su Jin Kim; Sanghoon Lee; Hyun Ju Oh; Jong Ik Hwang; Curie Ahn; Byeong Chun Lee Journal: Transgenic Res Date: 2018-12-14 Impact factor: 2.788
Authors: David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson Journal: Xenotransplantation Date: 2012 May-Jun Impact factor: 3.907
Authors: Kyle A Soltys; Kentaro Setoyama; Edgar N Tafaleng; Alejandro Soto Gutiérrez; Jason Fong; Ken Fukumitsu; Taichiro Nishikawa; Masaki Nagaya; Rachel Sada; Kimberly Haberman; Roberto Gramignoli; Kenneth Dorko; Veysel Tahan; Alexandra Dreyzin; Kevin Baskin; John J Crowley; Mubina A Quader; Melvin Deutsch; Chethan Ashokkumar; Benjamin L Shneider; Robert H Squires; Sarangarajan Ranganathan; Miguel Reyes-Mugica; Steven F Dobrowolski; George Mazariegos; Rajavel Elango; Donna B Stolz; Stephen C Strom; Gerard Vockley; Jayanta Roy-Chowdhury; Marilia Cascalho; Chandan Guha; Rakesh Sindhi; Jeffrey L Platt; Ira J Fox Journal: J Hepatol Date: 2016-12-24 Impact factor: 25.083